COVID-19 in multiple sclerosis: The Dutch experience: The Dutch experience

Floor C. Loonstra, Elske Hoitsma, Zoé L. E. van Kempen, Joep Killestein, Jop P. Mostert

Research output: Contribution to JournalArticleAcademicpeer-review

57 Citations (Scopus)

Abstract

Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch MS Taskforce of the Netherlands Society of Neurology. A total of 86 MS patients were reported, 43 of whom tested positive for COVID-19. Of 43 patients who tested positive, 22 patients were hospitalized. Three intensive care unit (ICU) admissions and four deaths were reported. Our findings show no apparent difference in disease-modifying treatment (DMT) use and COVID-19 disease course in Dutch MS patients. In addition, a clear link between low lymphocyte count and severe disease was not observed.
Original languageEnglish
Pages (from-to)1256-1260
Number of pages5
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume26
Issue number10
Early online date2020
DOIs
Publication statusPublished - 1 Sep 2020

Keywords

  • COVID-19
  • Multiple sclerosis
  • disease-modifying treatment
  • lymphocytes

Cite this